Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 4/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | BCL6 | P41182 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484324 | 0.96 | EGFR (0.62) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL8486071 | 0.96 | EGFR (0.62) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL8486755 | 0.95 | EGFR (0.65) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL8487772 | 0.86 | EGFR (0.62) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL8483882 | 0.86 | EGFR (0.63) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL8487643 | 0.86 | EGFR (0.63) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL8488324 | 0.85 | EGFR (0.60) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL6361454 | 0.85 | EGFR (0.66) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL8488643 | 0.83 | EGFR (0.65) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL8316917 | 0.83 | EGFR (0.71) | EGFRERBB2MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | disclosed |
| EP-0885227-A1 | PYRIMIDO 5,4-d]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032882-A1 | PYRIMIDO[5,4-d]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | disclosed |